GIVAUDAN-REG

European equity markets saw modest gains on Tuesday as falling oil prices eased inflation, with Givaudan’s shares rising 6% in the Swiss market and DAX edging higher.

Swiss market edges up despite geopolitical tension; Givaudan’s strategic Eurofragance deal shows targeted growth, while key Swiss firms navigate currency and regulatory headwinds.

Swiss markets fell 1.75% as pharma stocks like Roche and Novartis slid on regulatory fears, while tech and logistics gains offer a silver lining amid geopolitical uncertainty.